Journal article · 2025 · Open access

POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers

M.H. Chen, Mei‐Yu Chen, Sung Hae Chang, D.Y. Chen

Annals of the Rheumatic Diseases, 84, 347 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.05.430

Open full textCite this paper

In brief

“POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers” is a 2025 journal article by M.H. Chen and 3 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
0
Authors
4

Abstract

Background: Janus kinase inhibitors (JAKi) have demonstrated significant efficacy in the treatment of rheumatoid arthritis (RA). Tofacitinib, a first-generation JAKi targeting JAK1 and JAK3, has been reported to carry a higher malignancy risk compared to TNF-α inhibitors (TNFi) in RA patients aged 50 and older with at least one cardiovascular risk factor [1]. However, its effect on malignancy risk in Asian patients with high disease activity remains unclear. Objectives: This study aimed to assess the incidence of malignancies and identify associated risk factors in Asian RA patients receiving JAKi, conventional synthetic DMARDs (csDMARDs), biological DMARDs (bDMARDs). Methods: We retrospectively evaluated 3,804 patients with RA between 2001 and 2023. Patients with missing data or a history of prior cancer diagnosis were excluded. JAKi included tofacitinib, baricitinib, and upadacitinib. bDMARDs included TNFi, anti-IL-6 receptor monoclonal antibody (tocilizumab), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin (Ig) fusion protein (abatacept), and B-cell-depleting agents (anti-CD20 monoclonal antibody, rituximab). A time-dependent model was used to assess medication changes. JAKi and bDMARDs were only prescribed to subjects who were refractory to csDMARD therapy for over 6 months, as defined by Taiwan National Health Insurance. Results: During the 20,759 patient-years (PYs) of follow-up, a total of 161 of 2,904 patients (5.54 %) developed cancer, resulting in a crude incidence of malignancy of 7.76 events per 1000 PYs. Among the 161 patients with malignancy events, breast cancer was the most common (N = 29), followed by gastrointestinal tract cancer (N = 24), hematopoietic malignancies (N = 23), lung cancer (N = 21), colorectal cancer (N = 15) and renal/urinary tract cancer (N = 13). Among patients treated with tofacitinib, 14 malignancies occurred over 1,807 PYs, with an incidence rate of 7.75 per 1,000 PYs, which was lower than the incidence observed with TNFi (10.13 per 1,000 PYs), where 27 new cancer cases were reported over 2,665 PYs. Notably, older patients (aged over 65 years) receiving tofacitinib appeared to have a higher hazard of overall malignancies compared to those treated with TNFi; however, this difference did not reach statistical significance (adjusted HR: 2.56, 95% CI: 0.57–11.47, p=0.218). In the multivariable model, a higher baseline erythrocyte sedimentation rate was a significant risk factor for malignancy (aHR: 1.67. 95% CI: 1.02–2.75, p = 0.042). Conclusion: The results indicate no statistically significant difference in malignancy risk between Asian RA patients treated with tofacitinib and those receiving TNFi. Nonetheless, regular cancer screenings remain essential for patients undergoing JAKi or biologic therapy to ensure early detection and management. REFERENCES: [1] Ytterberg SR, Bhatt DL, Mikuls TR, Koch…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chen, M., Chen, M., Chang, S. H., & Chen, D. (2025). POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers. Annals of the Rheumatic Diseases, 84, 347. https://doi.org/10.1016/j.ard.2025.05.430

MLA 9

Chen, M.H., et al. “POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers.” Annals of the Rheumatic Diseases, vol. 84, 2025, p. 347. https://doi.org/10.1016/j.ard.2025.05.430.

Chicago

Chen, M.H., Mei‐Yu Chen, Sung Hae Chang, and D.Y. Chen. 2025. “POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers.” Annals of the Rheumatic Diseases 84: 347. https://doi.org/10.1016/j.ard.2025.05.430.

Harvard

Chen, M. et al. (2025) ‘POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers’, Annals of the Rheumatic Diseases, 84, p. 347. doi:10.1016/j.ard.2025.05.430.

IEEE

M. Chen, M. Chen, S. H. Chang, and D. Chen, “POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers,” Annals of the Rheumatic Diseases, vol. 84, p. 347, 2025, doi: 10.1016/j.ard.2025.05.430.

BibTeX

@article{chen2025tofacitinib,
  title     = {{POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers}},
  author    = {Chen, M.H. and Chen, Mei‐Yu and Chang, Sung Hae and Chen, D.Y.},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2025},
  volume    = {84},
  pages     = {347},
  doi       = {10.1016/j.ard.2025.05.430},
  url       = {https://doi.org/10.1016/j.ard.2025.05.430}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • tofacitinib
  • cancer risk
  • rheumatoid arthritis
  • JAK inhibitors
  • TNF-alpha inhibitors
  • Asian patients
  • high disease activity
  • cancer incidence

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Chen, M., Chen, M., Chang, S. H., & Chen, D. (2025). POS0033 Tofacitinib Does Not Increase Malignancy Risk Compared to TNF-a Inhibitors in Asian Patients with High-Disease-Activity Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers. Annals of the Rheumatic Diseases, 84, 347. https://doi.org/10.1016/j.ard.2025.05.430

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.

Who wrote this paper?

M.H. Chen, Mei‐Yu Chen, Sung Hae Chang, D.Y. Chen.

What is the DOI of this paper?

10.1016/j.ard.2025.05.430, permanently at https://doi.org/10.1016/j.ard.2025.05.430. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.